A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 89, Issue 1, 2003, Pages 95-98

  Hoffman, Mark A ^a,d   Blessing, John A ^b   Lentz, Samuel S ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOLASTATIN 10; PLATINUM;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CARDIOVASCULAR SYMPTOM; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG SENSITIVITY; ENDOCRINE DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; LIVER DISEASE; LUNG DISEASE; METABOLIC DISORDER; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OVARY CARCINOMA; PAIN; PHASE 2 CLINICAL TRIAL; PLEURODESIS; PRIORITY JOURNAL; RECURRENT DISEASE; UROGENITAL TRACT MALFORMATION; VOMITING;

EID: 0037384048     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00007-6     Document Type: Article

References (19)

1. Ozols R. Management of advanced ovarian cancer consensus Summary. Semin Oncol. 27:(Suppl 7):2000;47-49.
2. Thigpen J.T. Chemotherapy for advanced ovarian cancer overview of randomized trials . Semin Oncol. 27:(Suppl 7):2000;11-16.
3. Ozols R. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer. Semin Oncol. 27:(Suppl 7):2000;3-7.
4. Trimble E.L. Innovative therapies for advanced ovarian cancer. Semin Oncol. 27:(Suppl 7):2000;24-30.
5. McGuire W.P., Ozols R.F. Chemotherapy of advanced ovarian cancer. Semin Oncol. 25:1998;340-348.
6. Markman M., Hoskins W. Response to salvage chemotherapy in ovarian cancer a critical need for precise definitions of the treated population [editorial] . J Clin Oncol. 10:1992;513-514.
7. Ozols R.F. Treatment of recurrent ovarian cancer increasing options - "recurrent" results [editorial] . J Clin Oncol. 15:1997;2177-2180.
8. Anonymous. Investigator's Brochure for Dolastatin-10 (NSC 376128). NCI DCTD 1997.
9. Maki A., Mohammad R., Raza S., Saleh M., Govindaraju K.D., Pettit G.R., al-Katib A. Effect of dolastatin-10 on non-Hodgkin's lymphoma cell lines. Anti-Cancer Drugs. 7:1996;344-350.
10. Kalemkarian G.P., Ou X., Adil M.R., Rosati R., Khoulani M.M., Madan S.K., et al. Activity of dolastatin-10 against small-cell lung cancer in vitro and in vivo induction of apoptosis and bel-2 modification . Cancer Chemother Pharmacol. 43:1999;507-515.
11. Pitot HcC, Mcelroy E.A., Reid J.M., Ames M.M., Windebank A.J., Sloan J.A., et al. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res. 5:1999;525-531.
12. Aguayo A., Kraut E.H., Moore D.F., Hoff P.M., Wright J.J., Jones D., et al. Phase II study of dolastatin-10 administered intravenously every 21 days to patients with metastatic colorectal cancer (CRC) [abstract]. Proc Am Soc Clin Oncol. 19:2000;288a.
13. Margolin K.A., Longmage J., Synold T.W., Gandara D.R., Weber J., Gonzalez R., et al. Dolastatin-10 (DOLA) in metastatic melanoma (MEL) a phase II and pharmacokinetic trial of the California Cancer Consortium . Invest New Drugs. 19:2001;335-340.
14. Krug L.M., Miller V.A., Kalemkerian G.P., Kraut M.J., Ng K.K., Heelan R.T., et al. Phase II study of dolastatin-10 in patients with advanced non-small cell lung cancer. Ann Oncol. 11:2000;227-228.
15. Vaishampayan U., Glode M., Du W., Kraft A., Hdes G., Wright J., et al. Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clin Cancer Res. 6:2000;4205-4208.
16. Pitot H.C., Frytak S., Crogham G.A., Hillman D.W., Reid J.M., Arnes M., et al. Phase II study of dolastatin-10 in patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol. 21:2002;149b.
17. Verdier-Pinard P., Kepler J.A., Pettit G.R., Hamel E. Sustained intracellular retention of dolastatin-10 causes its potent antimitotic activity. Mol Pharmacol. 57:2000;180-187.
18. Horti J., Juhasz E., Istvan B. Preliminary results of a phase I trial of TZT-1027, an inhibitor of tubulin polymerization, patients with advanced non-small cell lung cancer [abstract]. Proc Am Assoc Cancer Res. 43:2002;552.
19. Senter P.D., Doronina S., Cerveny C., Chase D., Francisco J., Klussman K., et al. Cures and regression of established tumors with monoclonal antibody auristatin conjugates [abstract 2062]. Proc Am Assoc Cancer Res. 43:2000;414.